Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 25% during trading on Thursday . The stock traded as high as C$0.36 and last traded at C$0.35. 1,444,856 shares were traded during trading, an increase of 111% from the average session volume of 684,559 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Performance
The company has a market cap of C$30.49 million, a price-to-earnings ratio of -17.50 and a beta of 0.20. The stock’s fifty day moving average is C$0.12 and its two-hundred day moving average is C$0.09.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 3 Warren Buffett Stocks to Buy Now
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What is the Nasdaq? Complete Overview with History
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
